Fig. 5
From: IMB0901 inhibits muscle atrophy induced by cancer cachexia through MSTN signaling pathway
The therapeutic effect of IMB0901 in the C26 animal model. a The effect of IMB0901 on the survival rate of C2C12 cells. MTT assay was used to detect the survival rate of C2C12 cells after 24-h and 48-h treatment with IMB0901 at various concentrations. The values presented means ± SD from three experiments, each performed in triplicate. b The effect of IMB0901 on C26 tumor weights at endpoint. c The effect of IMB0901 on the tumor growth in in the group of C26 animal model and IMB0901 treatment. d The body weights of BALB/c mice at day 0~20. e The carcass weights of BALB/c mice. f, g The mass of quadriceps and gastrocnemius muscles in the C26 animal model. h The effect of IMB0901 on the expressions of two E3 ligases, Atrogin-1 and MuRF-1. Western blotting was used to detect the effect of IMB0901 on the expressions of two E3 ligases, Atrogin-1 and MuRF-1, in the quadriceps tissue. i Representative images of an H&E-stained cross-section of quadriceps from BALB/c mice and the average cross-sectional area (CSA) of the quadriceps fibers in the C26 animal model. There were three groups in this experiment: control, C26, C26 + IMB0901. The values presented means ± SD from 10 animals. **P < 0.01 compared to the control group, #P < 0.05 and ##P < 0.01 compared to the C26 group